Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,927 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
Jang J, Kim HK, Cho BC, Lee KH, Yun HJ, Woo IS, Song HS, Ryoo HM, Kim CH, Sun DS, Shin JW. Jang J, et al. Among authors: kim hk, kim ch. Cancer Chemother Pharmacol. 2017 May;79(5):873-880. doi: 10.1007/s00280-017-3289-6. Epub 2017 Mar 24. Cancer Chemother Pharmacol. 2017. PMID: 28341958 Clinical Trial.
A multicenter phase II study of belotecan, a new camptothecin analogue, in elderly patients with previously untreated, extensive-stage small cell lung cancer.
Yeo CD, Lee SH, Kim JS, Kim SJ, Kim SC, Kim YK, Kang HH, Yoon HK, Song JS, Moon HS, Kim JW, Kim KH, Shim BY, Kim CH. Yeo CD, et al. Among authors: kim sc, kim yk, kim ch, kim sj, kim js, kim jw, kim kh. Cancer Chemother Pharmacol. 2013 Oct;72(4):809-14. doi: 10.1007/s00280-013-2256-0. Epub 2013 Aug 6. Cancer Chemother Pharmacol. 2013. PMID: 23918044 Clinical Trial.
The safety and efficacy of second-line single docetaxel (75 mg/m²) therapy in advanced non-small cell lung cancer patients who were previously treated with platinum-based chemotherapy.
Shim BY, Kim CH, Song SH, Ahn MI, Hong EJ, Kim SW, Kim S, Jo MS, Cho DG, Cho KD, Yoo J, Kim HK. Shim BY, et al. Among authors: kim hk, kim sw, kim ch, kim s. Cancer Res Treat. 2005 Dec;37(6):339-43. doi: 10.4143/crt.2005.37.6.339. Epub 2005 Dec 31. Cancer Res Treat. 2005. PMID: 19956369 Free PMC article.
Expression of c-kit and p53 in non-small cell lung cancers.
Yoo J, Kim CH, Song SH, Shim BY, Jeong YJ, Ahn MI, Kim SW, Cho DG, Jo MS, Cho KD, Cho HJ, Kim HK. Yoo J, et al. Among authors: kim hk, kim sw, kim ch. Cancer Res Treat. 2004 Jun;36(3):167-72. doi: 10.4143/crt.2004.36.3.167. Epub 2004 Jun 30. Cancer Res Treat. 2004. PMID: 20396539 Free PMC article.
A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer.
Rhee CK, Lee SH, Kim JS, Kim SJ, Kim SC, Kim YK, Kang HH, Yoon HK, Song JS, Moon HS, Kim JW, Kim CH, Shim BY, Kim HK, Sun DS, Kim KH. Rhee CK, et al. Among authors: kim sc, kim yk, kim hk, kim ch, kim sj, kim js, kim jw, kim kh. Lung Cancer. 2011 Apr;72(1):64-7. doi: 10.1016/j.lungcan.2010.07.003. Epub 2010 Sep 15. Lung Cancer. 2011. PMID: 20832894 Clinical Trial.
Expression of caspase-3 and c-myc in non-small cell lung cancer.
Yoo Jy, Kim CH, Song SH, Shim BY, Jeong YJ, Ahn MI, Kim S, Cho DG, Jo MS, Cho KD, Cho HJ, Kang SJ, Kim HK. Yoo Jy, et al. Among authors: kim hk, kim ch, kim s. Cancer Res Treat. 2004 Oct;36(5):303-7. doi: 10.4143/crt.2004.36.5.303. Epub 2004 Oct 31. Cancer Res Treat. 2004. PMID: 20368820 Free PMC article.
5,927 results